Home＞REGULATORY
(Update) Similar “Treatment” Comparison Method Could Be Up for Discussion as New Pricing Scheme: Chuikyo(Sep.13.2017)
Chuikyo Drug Pricing Subcommittee |
The Central Social Insurance Medical Council, a health ministry reimbursement panel better known as Chuikyo, might discuss the creation of a new pricing scheme to work out the NHI prices of innovative medicines, such as ones likely to be launched in Japan ahead of the rest of the world ...
(LOG IN FOR FULL STORY)
-
With 253 Billion Yen Estimate Out, Chuikyo Members Prod MHLW to Vet Impact of Price Maintenance Premium
Sep.14
-
JGA President Sees Reduction in Number of Generic Drug Makers as “Inevitable”: Chuikyo
Sep.14
-
JPWA Expresses Concern Over Price Renegotiations, Calls for Guidelines to Curb Practice
Sep.14
-
Samurai Biotech Association Calls for NHI Price Increases When Sales Fall Below Forecasts: Chuikyo
Sep.14
-
- MHLW Panel Approves Increase in Raw Plasma Allocation to Nihon Pharmaceutical to 350,000 Liters Sep.22
-
Kaketsuken in Talks with “Several Entities” over Possible Biz Transfer: New Chief
Sep.21
-
MHLW to Consider Use of New Comprehensive Test System to Promote Practical Use of Genomic Medicine for Cancer: Official
Sep.21
- MHLW Issues Notification on Drug Criteria for Optimal Use Guidelines Sep.20
- Japan Drug Spending Logs 1st Fall in FY2016 Sep.19
- Teva’s Parkinson’s Med Delivers Positive Data in Japan PIII: Takeda(Sep.22)
- Medipal to Become JCR’s Top Shareholder, Poised to Form JV in US(Sep.22)
- Yasuhiro Onaka Tapped for Takeda’s Japan Sales Head(Sep.22)
- CSL Ramping Up Investment for New Product Development, 11% R&D-to-Sales Ratio “Appropriate”: CEO(Sep.22)
- MHLW Panel Approves Increase in Raw Plasma Allocation to Nihon Pharmaceutical to 350,000 Liters(Sep.22)
